Abstract
B cell lymphoma 2 (BCL2) is frequently overexpressed in lymphoid and myeloid malignancies. Targeting BCL2 using venetoclax has significantly improved outcomes in patients with chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), resulting in its approval in the first line in both these diseases. Its role in the management of mantle cell lymphoma, multiple myeloma, and diffuse large B cell lymphoma (DLBCL) is also being explored. This review of venetoclax details the pharmacodynamics, pharmacokinetics, clinical indications, dosing strategies, methods to prevent tumor lysis syndrome, and dose modifications. To prepare this review, we comprehensively searched various websites, including that of the United States Food and Drug Administration (US FDA), European Medicines Agency (EMA) drug manual, PubMed, and UpToDate using the search terms, “Venetoclax,” “AML,” “CLL,” “Pharmacology,” and “hematolymphoid malignancy.” We shortlisted all the full-text articles published in the preceding 10 years. Out of a total of 397 manuscripts identified, we included 57. We also incorporated information from the abstracts and various conference proceedings.

This publication has 52 references indexed in Scilit: